Table 2.
Risk of Dementia and Its Subtypes According to Serum NT‐proBNP Levels, 2002‐2012
| NT‐proBNP (pg/mL) | People at Risk | No. of Events | Crude Incidence Per 1000 Person‐Years | Hazard Ratio (95% CI) | ||
|---|---|---|---|---|---|---|
| Model 1 | Model 2 | Model 3 | ||||
| All‐cause dementia | ||||||
| ≤54 | 514 | 55 | 11.2 | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| 55 to 124 | 595 | 141 | 27.0 | 1.76 (1.28‐2.41) | 1.66 (1.21‐2.29) | 1.66 (1.21‐2.29) |
| 125 to 299 | 336 | 111 | 42.1 | 2.03 (1.44‐2.85) | 1.65 (1.16‐2.34) | 1.69 (1.19‐2.39) |
| ≥300 | 190 | 70 | 61.0 | 3.02 (2.08‐4.37) | 2.38 (1.58‐3.58) | 2.46 (1.63‐3.71) |
| P for trend | <0.001 | <0.001 | <0.001 | |||
| 1‐SD increment in log (serum NT‐proBNP levels) | 1635 | 377 | 27.1 | 1.43 (1.29‐1.59) | 1.36 (1.20‐1.55) | 1.38 (1.21‐1.58) |
| Alzheimer disease | ||||||
| ≤54 | 514 | 32 | 6.5 | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| 55 to 124 | 595 | 104 | 19.9 | 2.03 (1.36‐3.04) | 2.00 (1.33‐3.00) | 2.00 (1.33‐2.99) |
| 125 to 299 | 336 | 75 | 28.5 | 2.03 (1.32‐3.13) | 1.82 (1.17‐2.84) | 1.90 (1.22‐2.96) |
| ≥300 | 190 | 36 | 31.4 | 2.41 (1.47‐3.96) | 2.23 (1.31‐3.82) | 2.43 (1.41‐4.16) |
| P for trend | 0.001 | 0.01 | 0.003 | |||
| 1‐SD increment in log (serum NT‐proBNP levels) | 1635 | 247 | 17.8 | 1.30 (1.13‐1.49) | 1.30 (1.11‐1.53) | 1.35 (1.14‐1.59) |
| Vascular dementia | ||||||
| ≤54 | 514 | 13 | 2.6 | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| 55 to 124 | 595 | 28 | 5.4 | 1.72 (0.88‐3.36) | 1.57 (0.81‐3.07) | 1.57 (0.81‐3.07) |
| 125 to 299 | 336 | 35 | 13.3 | 3.53 (1.81‐6.88) | 2.51 (1.26‐4.99) | 2.52 (1.26‐5.03) |
| ≥300 | 190 | 26 | 22.6 | 5.92 (2.94‐11.90) | 3.54 (1.63‐7.68) | 3.55 (1.64‐7.72) |
| P for trend | <0.001 | <0.001 | <0.001 | |||
| 1‐SD increment in log (serum NT‐proBNP levels) | 1635 | 102 | 7.3 | 1.71 (1.42‐2.05) | 1.51 (1.18‐1.92) | 1.51 (1.19‐1.93) |
The SD of log‐transformed NT‐proBNP levels (pg/mL) was 1.058. Model 1: adjusted for age and sex. Model 2: adjusted for age, sex, education level, systolic blood pressure, use of antihypertensive agents, use of heart disease agents, diabetes mellitus, hypercholesterolemia, body mass index, estimated glomerular filtration rate, atrial fibrillation, history of stroke, smoking habit, alcohol intake, and regular exercise. Model 3: adjusted for the covariates included in model 2 plus high‐sensitivity C‐reactive protein. NT‐proBNP indicates N‐terminal pro–B‐type natriuretic peptide.